Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
This article was originally published in The Pink Sheet
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
You may also be interested in...
Big Pharma Set To Compete For German Merck's Consumer Health Unit
German Merck is seeking a buyer or partner for its consumer health unit, which brought in sales of €860m last year and includes big vitamin brands Seven Seas and Neurobion.
Oral Contraceptive Switch Advocates Reject User Age As Approval Factor
FDA could soon receive an NDA from non-profit research group Ibis Reproductive Health and HRA Pharma, for an oral contraceptive switch in the US.
OTC Evolution For Prestige Brands Combines Near- And Long-Term Strategies
BC, Goody's, Monistat marketer boosts domestic and international OTC revenues immediately with C.B. Fleet acquisition, looks ahead to manufacturing expansion.